Uterine Corpus Sarcoma — Trials

Uterine Corpus Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 22
Ph III recruiting: 4
Growth YoY: —
Industry share: 15%
Top sponsor: Assistance Publique Hopitaux De Marseille
Termination share: 24.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02601209	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma	terminated	Phase 1 / Phase 2	151	National Cancer Institute (NCI)NIH	1	Aug 23, 2022	clinicaltrials

Data updated 22 days agoSource updated Aug 23, 2022source: clinicaltrials